Theriva Biologics Inc.

03/23/2026 | Press release | Distributed by Public on 03/23/2026 11:25

Theriva™ Biologics anuncia el resultado positivo de la reunión de cierre de la fase 2 con la FDA de EE. UU. sobre el diseño de un ensayo de fase 3 del VCN-01 para el[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Theriva Biologics Inc. published this content on March 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 23, 2026 at 17:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]